EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Follistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling

Xiaoxian Shi iD, Zuyan Fan iD, Min Qu, Chunjie Lin, Zhiheng Ji, Caiwei Tan, Biqi Dai, Rushan Chen iD, Yixuan Du, Yizhong Bao, Zhifan Ding, Liqun Xia und 13 weitere

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2603564123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Xiaoxian Shi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Life Sciences Institute, Zhejiang University, Hangzhou 310058, Zhejiang, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Prostatic Neoplasms, Follistatin, Receptors, Androgen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National key R & D program of China, the National Natural Science Foundation of China, Zhejiang Provincial NSF of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in advanced prostate cancer. Here we identify follistatin (FST), TGFβ superfamily antagonist, as a key driver of AR-independence and treatment resistance. During anti-AR therapy, cancer cells progressively lose the positive feedback loop between AR and BMP signaling, leading to FST upregulation that further suppresses this circuit. FST antagonizes BMP11-dependent AR maintenance and upregulates the lineage plasticity regulator SOX9, conferring resistance to enzalutamide while promoting stem-like properties and metastatic capabilities. FST also remodels the tumor microenvironment by driving osteoclastogenesis and compromising T cell effector function. Clinically, FST inversely correlates with PSA levels and associates with poor outcomes in enzalutamide-treated patients. We developed FST-Trap, which effectively neutralizes FST, resensitizes resistant tumors to AR-targeted therapy, and enhances immunotherapy efficacy. This establishes FST as both a biomarker and therapeutic target for AR-independent prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentProstatic NeoplasmsFollistatinReceptors, AndrogenBone Morphogenetic ProteinsMaleHumansAnimalsSignal TransductionNitrilesBenzamidesCell Line, TumorDrug Resistance, NeoplasmMiceSOX9 Transcription FactorPhenylthiohydantoinGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

AR-independent prostate cancerBMP signalinganti-AR resistancebiomarkermetastatic microenvironment

Substanzen

FollistatinNitrilesReceptors, AndrogenBenzamidesBone Morphogenetic ProteinsenzalutamideSOX9 Transcription FactorPhenylthiohydantoinSOX9 protein, human

Autor:innen und Institutionen

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Life Sciences Institute, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
  • Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Institute of Pharmacology and Toxicology, Zhejiang University College of Pharmaceutical Sciences, Hangzhou 310058, China.
  • Zhejiang Key Laboratory of Geriatrics and Geriatrics Institute of Zhejiang Province, Zhejiang Hospital, Hangzhou 310030, China.

ORCID-Profile: Xiaoxian Shi, Zuyan Fan, Rushan Chen, Hongliang Gao, Wei Xie, Dong Fang, Weijie Zhang, Deli Huang, Xu Gao, Gonghui Li, Jing Li, Wenjing Su

Förderung

  • the National key R & D program of China
  • the National Natural Science Foundation of China
  • Zhejiang Provincial NSF of China

Zitieren

APA

Shi, X., Fan, Z., Qu, M., Lin, C., Ji, Z., Tan, C., Dai, B., Chen, R., Du, Y., Bao, Y., Ding, Z., Xia, L., Liu, F., Gao, H., Cao, T., Xie, W., Fang, D., Zhang, W., Huang, D., …, & Su, W. (2026). Follistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2603564123

Vancouver

Shi X, Fan Z, Qu M, Lin C, Ji Z, Tan C, et al. Follistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2603564123

BibTeX
@article{Shi2026,
  author = {Shi, Xiaoxian and Fan, Zuyan and Qu, Min and Lin, Chunjie and Ji, Zhiheng and Tan, Caiwei and Dai, Biqi and Chen, Rushan and Du, Yixuan and Bao, Yizhong and Ding, Zhifan and Xia, Liqun and Liu, Furong and Gao, Hongliang and Cao, Tianyu and Xie, Wei and Fang, Dong and Zhang, Weijie and Huang, Deli and Chen, Jun and Gao, Xu and Feng, Xinhua and Li, Gonghui and Li, Jing and Su, Wenjing},
  title = {Follistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2603564123}
}
Kostenlos starten →